Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Top Cited Papers
- 9 January 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 94 (1), 110-118
- https://doi.org/10.1161/01.res.0000109415.17511.18
Abstract
Calcineurin (PP2B) is a calcium/calmodulin-activated, serine-threonine phosphatase that transmits signals to the nucleus through the dephosphorylation and translocation of nuclear factor of activated T cell (NFAT) transcription factors. Whereas calcineurin-NFAT signaling has been implicated in regulating the hypertrophic growth of the myocardium, considerable controversy persists as to its role in maintaining versus initiating hypertrophy, its role in pathological versus physiological hypertrophy, and its role in heart failure. To address these issues, NFAT-luciferase reporter transgenic mice were generated and characterized. These mice showed robust and calcineurin-specific activation in the heart that was inhibited with cyclosporin A. In the adult heart, NFAT-luciferase activity was upregulated in a delayed, but sustained manner throughout eight weeks of pathological cardiac hypertrophy induced by pressure-overload, or more dramatically following myocardial infarction-induced heart failure. In contrast, physiological hypertrophy as produced in two separate models of exercise training failed to show significant calcineurin-NFAT coupling in the heart at multiple time points, despite measurable increases in heart to body weight ratios. Moreover, stimulation of hypertrophy with growth hormone–insulin-like growth factor-1 (GH-IGF-1) failed to activate calcineurin-NFAT signaling in the heart or in culture, despite hypertrophy, activation of Akt, and activation of p70 S6K. Calcineurin Aβ gene–targeted mice also showed a normal hypertrophic response after GH-IGF-1 infusion. Lastly, exercise- or GH-IGF-1–induced cardiac growth failed to show induction of hypertrophic marker gene expression compared with pressure-overloaded animals. Although a direct cause-and-effect relationship between NFAT-luciferase activity and pathological hypertrophy was not proven here, our results support the hypothesis that separable signaling pathways regulate pathological versus physiological hypertrophic growth of the myocardium, with calcineurin-NFAT potentially serving a regulatory role that is more specialized for maladaptive hypertrophy and heart failure.Keywords
This publication has 33 references indexed in Scilit:
- Cardiac Hypertrophy: The Good, the Bad, and the UglyAnnual Review of Physiology, 2003
- Lifetime Risk for Developing Congestive Heart FailureCirculation, 2002
- Akt Signaling Mediates Postnatal Heart Growth in Response to Insulin and Nutritional StatusPublished by Elsevier BV ,2002
- Calcineurin and cardiac hypertrophy: Where have we been? Where are we going?The Journal of Physiology, 2002
- NFAT SignalingCell, 2002
- Regulation of cell size in growth, development and human disease: PI3K, PKB and S6KBioEssays, 2002
- GENERAL CARDIOLOGY: The athlete's heartHeart, 2001
- Cytoplasmic Signaling Pathways That Regulate Cardiac HypertrophyAnnual Review of Physiology, 2001
- Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4Nature, 1996
- The epidemiology of heart failure: The Framingham StudyJournal of the American College of Cardiology, 1993